Pharmaids Pharmaceuticals share news and announcements
BSE: 524572Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹28.29.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹102 Cr2,774th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 1 Jun 2026
- 2.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 12 Aug 2026
- −8.5%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹6.70 crore of one-off items, the largest of them in the quarter to Jun 2026.
- −21.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 12 Aug 2026
- −15.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 1 Jun 2026
- 0.44
- Volume, BSEVolume. Shares traded on the last trading day.
- 1,482
Pharmaids Pharmaceuticals share news and announcements
617 announcements, routine notices left out, newest first. Page 2 of 13.
Aug 2025
7 Aug · Announcement under Regulation 30 (LODR)-Open Offer - Updates
4 Aug · Board meeting
Meeting on 7 Aug 2025: quarterly results1 Aug · Announcement under Regulation 30 (LODR)-Open Offer - Updates
Jul 2025
30 Jul · Announcement under Regulation 30 (LODR)-Open Offer - Updates
25 Jul · Announcement under Regulation 30 (LODR)-Open Offer - Updates
14 Jul · Meeting
4 Jul · Board meeting
May 2025
20 May · Board meeting
Meeting on 23 May 2025: audited results
Mar 2025
24 Mar · Intimation Under Regulation 8(2) Of SEBI (PIT) Regulation, 2015 Regarding Amendment In Fair Disclosure Code
Feb 2025
12 Feb · Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
7 Feb · Board meeting
Meeting on 12 Feb 2025: quarterly results6 Feb · Outcome Of The Circular Resolution Passed By The Board Of Directors Of The Company On February 06, 2025
Jan 2025
10 Jan · Announcement under Regulation 30 (LODR)-Open Offer - Updates
3 Jan · Announcement under Regulation 30 (LODR)-Open Offer - Updates
3 Jan · Detailed Public Statement
Dec 2024
27 Dec · Announcement under Regulation 30 (LODR)-Public Announcement-Open Offer
27 Dec · Public Announcement - Open Offer
9 Dec · Intimation Of Receipt Of National GLP Certification For Material Subsidiary Of The Company.